Fluoxetine vs Sertraline

Both fluoxetine and sertraline demonstrate robust efficacy for major depressive disorder in numerous randomized controlled trials. The 2018 Cipriani meta-analysis found sertraline to be among the most effective and best-tolerated antidepressants, while fluoxetine also performed well with a particularly strong evidence base.

Fluoxetine is FDA-approved for MDD (including adolescent MDD), OCD (including pediatric OCD), panic disorder, bulimia nervosa ^[9], and treatment-resistant depression (in combination with olanzapine as Symbyax). Sertraline is FDA-approved for MDD, OCD, panic disorder, PTSD, social anxiety disorder, and PMDD.

For pediatric depression, fluoxetine holds a unique position as the first-line recommended treatment for adolescent depression by the American Academy of Child and Adolescent Psychiatry. It is the best-studied SSRI in children and adolescents, with the Treatment for Adolescents with Depression Study (TADS) ^[4] providing landmark efficacy data.

Fluoxetine's long half-life provides a self-tapering effect, which means missed doses are less clinically impactful and discontinuation syndrome is significantly less common compared to sertraline and other shorter-acting SSRIs.

For bulimia nervosa ^[9], fluoxetine is the only SSRI with FDA approval, typically used at higher doses (60 mg/day). Sertraline does not carry this indication.

Both medications share the common SSRI side effect profile including nausea, headache, insomnia, and sexual dysfunction ^[2][3]. However, there are notable differences.

Fluoxetine tends to be more activating (stimulating) than sertraline, which can be beneficial for patients with fatigue and lethargy but may worsen insomnia and anxiety, particularly during the first weeks of treatment. It has the longest half-life of any SSRI, meaning side effects take longer to resolve when they occur, but also that discontinuation syndrome is extremely rare.

Sertraline's most distinguishing side effect is GI disturbance, particularly diarrhea, which occurs in approximately 20% of patients. This is attributed to serotonin's effects on the GI tract and sertraline's mild dopamine reuptake inhibition.

Fluoxetine is a potent inhibitor of CYP2D6, giving it significant potential for drug-drug interactions with medications metabolized by this enzyme (including many other psychiatric medications, opioids, and beta-blockers). Sertraline is a weaker CYP2D6 inhibitor ^[2][5], resulting in fewer drug interaction concerns.

Sexual dysfunction occurs with both medications at similar rates (approximately 10-15%). Both carry the FDA black box warning for increased suicidality risk in children, adolescents, and young adults under 25.

Weight effects are similar — both are considered weight-neutral SSRIs, though modest weight gain can occur with long-term use.

Both medications are available as very affordable generics. Generic fluoxetine costs approximately $4-$10 per month. Generic sertraline costs approximately $4-$12 per month. Both are among the least expensive prescription medications available.

Both are included on $4 generic lists at major pharmacies, covered by all insurance plans, and rarely require prior authorization. Cost is not a differentiating factor.

Both are taken orally once daily. Fluoxetine is available in 10, 20, and 40 mg capsules, 20 mg tablets, and an oral solution. A 90 mg weekly capsule (Prozac Weekly) is also available for patients stabilized on 20 mg daily. Sertraline comes in 25, 50, and 100 mg tablets and an oral concentrate.

Fluoxetine's extremely long half-life means that missing occasional doses has minimal clinical impact, which can be advantageous for patients with inconsistent adherence. Neither requires routine blood monitoring.

Fluoxetine may be preferred for adolescent depression (strongest pediatric evidence), patients with a history of medication non-adherence (long half-life is forgiving), patients concerned about discontinuation syndrome ^[10], and patients with bulimia nervosa.

Sertraline may be preferred for patients with PTSD or PMDD (specific FDA approvals), patients on multiple medications (fewer drug interactions), pregnant women (often considered first-line based on pregnancy safety data), and patients who need to switch medications quickly (shorter half-life allows faster transitions).

Fluoxetine's long half-life is a double-edged sword: it protects against discontinuation syndrome ^[10] but means that if the drug needs to be cleared from the body (for drug interactions or switching to an MAOI), a 5-week washout period is required. Sertraline's shorter half-life allows for a 2-week washout.

Both are excellent first-line antidepressants. If one is ineffective or causes intolerable side effects, switching to the other is a well-supported clinical strategy.